Back to top
more

Pfizer (PFE)

(Real Time Quote from BATS)

$29.99 USD

29.99
5,125,521

+0.49 (1.66%)

Updated Jul 17, 2024 10:16 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 35% (163 out of 250)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Arpita Dutt headshot

Pharma Stock Roundup: Merck, Pfizer Report Q1 Earnings, J&J Talc Powder Lawsuit

by Arpita Dutt

Major pharma companies like Pfizer (PFE) and Merck reported Q1 results last week.

    Swarup Gupta headshot

    Dow 30 Stock Roundup: Apple, Merck Beat; Pfizer Misses on Revenues

    by Swarup Gupta

    The Dow traded inside a tight band during a week marked by key earnings releases and legislative developments.

      Merck vs. Pfizer: Which Stock Looks Better Post-Earnings?

      by Zacks Equity Research

      Pfizer is better positioned than Merck and thus calls for investors' attention post earnings.

        Aerie (AERI) Posts Wider-Than-Expected Q1 Loss, Expenses Up

        by Zacks Equity Research

        Aerie Pharmaceuticals, Inc. (AERI) posted first-quarter 2017 loss of 76 cents per share (including stock-based compensation), wider than the Zacks Consensus Estimate of a loss of 74 cents.

          Momenta (MNTA) Q1 Loss Narrower than Expected, Sales Beat

          by Zacks Equity Research

          Momenta Pharmaceuticals Inc. (MNTA) reported loss of 46 cents per share in the first quarter of 2017,which was narrower than the Zacks Consensus Estimate loss of $1.09. In fact, the company posted a loss of 35 cents in the year-ago quarter as well.

            Drug Stock Q1 Earnings Releases on May 4: ZTS, REGN & More

            by Zacks Equity Research

            Here we have four pharma companies that are set to report first-quarter results on May 4. Let's see how things are shaping up for them.

              Merck (MRK) Beats on Q1 Earnings & Sales, Ups Annual View

              by Zacks Equity Research

              Merck & Co., Inc. (MRK) reported first-quarter 2017 earnings of 88 cents per share, which beat the Zacks Consensus Estimate of 83 cents.

                Pfizer and Apple In Focus

                by Zacks Equity Research

                Pfizer and Apple In Focus

                  Mark Vickery headshot

                  On Pfizer and Apple: 2 Titanic Stocks Reporting Earnings Today

                  by Mark Vickery

                  Instead of another run-down of the high number of companies reporting today, I'd like to focus on one company having reported before the bell and one coming after the close: Pfizer (PFE) and Apple (AAPL).

                    Pfizer (PFE) Q1 Earnings Beat, Sales Lag, 2017 View Intact

                    by Zacks Equity Research

                    Pfizer, Inc. (PFE) reported first-quarter 2017 adjusted earnings per share of 69 cents, which beat the Zacks Consensus Estimate of 67 cents by 3%.

                      Zacks Investment Ideas feature highlights: Tesla, Pfizer, Apple and Facebook

                      by Zacks Equity Research

                      Zacks Investment Ideas feature highlights: Tesla, Pfizer, Apple and Facebook

                        Pfizer (PFE) Tops Q1 Earnings Estimates, Misses Sales

                        by Zacks Equity Research

                        PFE beat first quarter earnings which came in at 69 cents while our consensus called for EPS of 67 cents.

                          Drug Stocks Q1 Earnings Slated for May 2: MRK, PFE & GILD

                          by Zacks Equity Research

                          The Q1 earnings season is in full swing with financial results from 288 S&P 500 members or 63.8% of the index already out as of Apr 28, 2017.

                            Brian Bolan headshot

                            The Week Ahead In One Click

                            by Brian Bolan

                            A look at the important economic data and earnings that are headed your way this week.

                              Vertex (VRTX) Q1 Earnings Top, CF Products Sales Strong

                              by Zacks Equity Research

                              Vertex Pharmaceuticals Incorporated (VRTX) reported first-quarter 2017 earnings per share of 13 cents (including the impact of stock-based compensation expense), which beat the Zacks Consensus Estimate of 4 cents.

                                Should You Buy Pfizer (PFE) Ahead of Earnings?

                                by Zacks Equity Research

                                Pfizer (PFE) is seeing encouraging earnings estimate revision activity as of late and carries a favorable rank, positioning the company for a likely beat this season.

                                  Arpita Dutt headshot

                                  Pharma Stock Roundup: Lilly, Bristol-Myers, Novartis Q1 Earnings & More

                                  by Arpita Dutt

                                  Several major pharma companies including Lilly (LLY) and Bristol-Myers reported Q1 results this week.

                                    Bristol-Myers (BMY) Beats on Q1 Earnings, Ups 2017 View

                                    by Zacks Equity Research

                                    Bristol-Myers Squibb Company's (BMY) first-quarter 2017 earnings of 84 cents per share beat the Zacks Consensus Estimate of 72 cents and surged 14% from the year-ago period.

                                      Pfizer (PFE) Q1 Earnings: Will it Pull Off a Surprise?

                                      by Zacks Equity Research

                                      Pfizer, Inc. (PFE) will report first-quarter 2017 earnings on May 2, before market open. Last quarter, the company delivered a negative earnings surprise of 6.0%.

                                        Sweta Killa headshot

                                        Is Pain Ahead for Healthcare ETFs After Weak JNJ Q1?

                                        by Sweta Killa

                                        Results from Johnson and Johnson could be a warning sign for other drug makers, which are scheduled to report this week and the next.

                                          AbbVie's (ABBV) Cancer Candidate Fails in Phase III Studies

                                          by Zacks Equity Research

                                          AbbVie Inc. announced disappointing top-line results from two phase III studies evaluating veliparib in combination with chemotherapy for treatment of patients with squamous non-small cell lung cancer and triple negative breast cancer.

                                            Is J&J's Pharma Sales Slowdown a Warning for Other Players?

                                            by Zacks Equity Research

                                            Johnson & Johnson (JNJ) reported mixed first-quarter 2017 earnings results on Tuesday.

                                              Sweta Killa headshot

                                              Lackluster J&J Q1 Pushes Healthcare ETFs Down

                                              by Sweta Killa

                                              Johnson & Johnson continued its long streak of earnings beat but lagged our revenue estimate again on sluggish drug sales.

                                                Why Is Pfizer (PFE) Up 8.7% Since the Last Earnings Report?

                                                by Zacks Equity Research

                                                Pfizer (PFE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                                                  Roche's (RHHBY) Cancer Drug Gets FDA Nod for Label Expansion

                                                  by Zacks Equity Research

                                                  Roche Holding AG's (RHHBY) unit, Genentech, announced that its drug Tecentriq (atezolizumab) has received FDA approval on an accelerated basis for initial treatment of people with advanced urothelial carcinoma (mUC).